BRISTOL MYERS SQUIBB HOLDINGS IRELAND has a total of 144 patent applications. It increased the IP activity by 33.0%. Its first patent ever was published in 1991. It filed its patents most often in Australia, EPO (European Patent Office) and Norway. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are OTHERA PHARMACEUTICALS INC, BEIJING INCREASE INNOVATIVE DRUG RES CO LTD and OOO KONSORTSIUM PIK.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 31 | |
#2 | EPO (European Patent Office) | 23 | |
#3 | Norway | 8 | |
#4 | Serbia | 7 | |
#5 | Chile | 6 | |
#6 | Hong Kong | 6 | |
#7 | Japan | 6 | |
#8 | Mexico | 6 | |
#9 | China | 5 | |
#10 | Hungary | 5 | |
#11 | Peru | 5 | |
#12 | Canada | 4 | |
#13 | Taiwan | 4 | |
#14 | Argentina | 3 | |
#15 | Brazil | 3 | |
#16 | Israel | 3 | |
#17 | Republic of Korea | 3 | |
#18 | Singapore | 3 | |
#19 | EAPO (Eurasian Patent Organization) | 2 | |
#20 | Luxembourg | 2 | |
#21 | Montenegro | 2 | |
#22 | Russian Federation | 2 | |
#23 | Colombia | 1 | |
#24 | Croatia | 1 | |
#25 | India | 1 | |
#26 | New Zealand | 1 | |
#27 | Philippines | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Medical technology | |
#5 | Packaging and shipping | |
#6 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Jia Jingpin | 22 |
#2 | Patel Jatin | 21 |
#3 | Frost Charles | 21 |
#4 | Vema-Varapu Chandra | 20 |
#5 | Perrone Robert Kevin | 18 |
#6 | Nikfar Faranak | 14 |
#7 | Koo Otilia May Yue | 13 |
#8 | Belema Makonen | 12 |
#9 | Kim Soojin | 11 |
#10 | Tao Jing | 11 |
Publication | Filing date | Title |
---|---|---|
MX2016004078A | Hiv treatment formulation of atazanavir and cobicistat. | |
AU2013323435A1 | Apixaban liquid formulations | |
AU2013231052A1 | Crystalline forms of n-(tert-butoxycarbonyl)-3-methyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-l-prolinamide | |
AU2006235960A1 | Low dose entecavir formulation and use | |
AU2006233208A1 | Hepatitis C virus inhibitors | |
ME02261B | Process for preparing atazanavir bisulfate and novel forms |